Journal Information
Vol. 92. Issue 5.
Pages 245-246 (May 2017)
Share
Download PDF
More article options
Vol. 92. Issue 5.
Pages 245-246 (May 2017)
Letter to the Editor
The diabetic retinopathy clinical research network analysis of the cost-effectiveness of aflibercept, bevacizumab and ranibizumab for the treatment of diabetic macular oedema and its application in Spain
Análisis del DRCR Network sobre coste-efectividad de aflibercept, bevacizumab y ranibizumab para el tratamiento de edema macular diabético y su aplicación en España
Visits
84
A. Navarro-Navarroa,
, D. Saloma, J.J. Martínez-Toldosb, P. Udaondoc, C. Fernández-Martínezb, L. Gutiérrez-Ariasa, A. Hervása, R. Rodrigod
Corresponding author
a Servicio de Oftalmología, Hospital de Manises, Manises, Valencia, Spain
b Servicio de Oftalmología, Hospital General Universitario de Elche, Elche, Alicante, Spain
c Servicio de Oftalmología, Hospital Universitario La Fe, Valencia, Spain
d Grupo de Biomedicina Molecular, Celular y Genómica, Instituto de Investigación Sanitaria La Fe, Valencia, Spain
This item has received
Article information
These are the options to access the full texts of the publication Archivos de la Sociedad Española de Oftalmología (English Edition)
Subscriber
Subscribe
Purchase
Contact
Phone for subscriptions and reporting of errors
From Monday to Friday from 9 a.m. to 6 p.m. (GMT + 1) except for the months of July and August which will be from 9 a.m. to 3 p.m.
Calls from Spain
932 415 960
Calls from outside Spain
+34 932 415 960
E-mail